Photogen Technologies Names Richard T. Dean, Ph.D. to its Board of Directors

Photogen Technologies Names Richard T. Dean, Ph.D. to its Board of Directors 


SAN DIEGO, Nov. 7  /PRNewswire-FirstCall/ -- Photogen Technologies, Inc. 
announced today that it has appointed Richard T. Dean, Ph.D. to its Board of
Directors.  Dr. Dean's appointment was effective as of October 27, 2003.

"Dick brings with him excellent operating experience in the radiopharmaceutical
and diagnostic imaging fields which will be very beneficial to Photogen as we
proceed with the marketing and sale of our new imaging product, Imagent(R),"
said Taffy J. Williams, Ph.D., President and Chief Executive Officer of
Photogen.  Dr. Williams said, "The Board and I are looking forward to working
with Dr. Dean as Photogen continues to develop and market its platform of
imaging products."

Dr. Dean is currently an investment advisor to NeoMed Fund, Oslo, Norway, a
healthcare focused fund, and previously served as Head of Strategic Business
Development, Diagnostic and Radiopharmaceuticals, Schering AG, Berlin, Germany. 
He also has extensive experience in the field of diagnostic imaging, having
previously held executive positions with Mallinckrodt Medical and Centocor, a
subsidiary of Johnson & Johnson.  Dr Dean founded Diatide Inc., a company
focused on discovering and developing novel radiopharmaceutical products, which
he took public and ultimately sold to Schering AG.  Dr. Dean received his Ph.D.
in Chemistry from the University of California, Berkeley.

About Photogen

Photogen Technologies, Inc. develops and markets a platform of innovative
imaging products.  The company recently acquired the medical imaging business of
Alliance Pharmaceutical Corp., led by Imagent(R) (perflexane lipid
microspheres), an FDA approved ultrasound imaging product.  Photogen's
development programs use a versatile iodinated nanoparticulate formulation that
shows promise as a subcutaneous, intravenous or intra-arterial agent for both
cardiovascular imaging and lymphography (the diagnosis of cancer metastasizing
to lymph nodes). PH-50, which is entering Phase 1 clinical studies, has
potential benefits when used with conventional or computed tomography (CT)
angiography to address the need for early detection of coronary artery disease,
cancer and other diseases affecting the body's arteries and organs.  N1177,
which is entering Phase 2 clinical studies, has potential applications for the
diagnosis and staging of cancers such as breast, prostate, lung, melanoma,
uterine, cervical, and head and neck cancer.

Statements in this release that are not strictly historical are
"forward-looking" statements made pursuant to the safe harbor provision of the
Private Securities Litigation Reform Act of 1995. Forward-looking statements
involve known and unknown risks that may cause Photogen's actual results in the
future to differ materially from expected results. These risks and uncertainties
include the ability of the company to:  obtain necessary financing to support
its development and commercialization programs, maintain and defend intellectual
property protection for its proprietary products, avoid infringing intellectual
property rights of third parties, successfully market its approved product,
develop additional products and obtain regulatory approval for their use, and
manufacture or obtain supplies of drug product. These and other risks are
described and qualified in their entirety by cautionary language and risk
factors set forth in the company's filings from time to time with the Securities
and Exchange Commission.

   Brooks Boveroux, CFO
   Photogen Technologies, Inc.
   [phone]

   Brian Ritchie
   EURO RSCG Life NRP
   [phone]


DATASOURCE: Photogen Technologies, Inc.



CONTACT:  Brooks Boveroux, CFO of Photogen Technologies, Inc.,

[phone]; or Brian Ritchie EURO RSCG Life NRP, [phone], for

Photogen Technologies, Inc.

Copyright